News & Updates

Research to be presented highlights the strong therapeutic potential of integrin agonists in treatment of lupus nephritis, focal segmental glomerulosclerosis, and other rare kidney disorders MIAMI--(BUSINESS WIRE)--Allosite Therapeutics, a biotechnology company...

149 Bio, LLC, a clinical-stage therapeutics company focused on developing breakthrough treatments for kidney diseases and other immune conditions with high unmet need, announced today that it has acquired GB1275, a first-in-class orally bioavailable integrin activator, and the associated CD11b program in its entirety from Gossamer Bio, Inc.

149 Bio, LLC has announced its therapeutic target for kidney diseases as integrin heterodimer alpha3beta1 (α3β1) that is highly expressed on kidney podocytes and is essential for podocyte attachment and health. The company also disclosed identification of novel allosteric agonist antibodies that target integrin α3β1 and enhance integrin-dependent ligand binding and cell adhesion.